Brief: Medesis Pharma Says Positive Results In Development Programme Of NanoManganese

Medesis Pharma SA

20/04/2022 17:37

April 20 (Reuters) - Medesis Pharma SA  ALMDP.PA :
    * POSITIVE RESULTS IN DEVELOPMENT PROGRAMME FOR DRUG
CANDIDATE
NANOMANGANESE, AS RADIOPROTECTIVE AGENT IN CANCERS TREATED WITH
RADIOTHERAPY
    * NANOMANGANESE SIGNIFICANTLY INCREASED THE SURVIVAL OF
MICE,
DEMONSTRATING ITS ANTI-RADICAL ACTIVITY AND SUPPORTING ITS
POTENTIAL TO PROTECT HEALTHY TISSUE FROM RADIATION TOXICITY
    * NANOMANGANESE TREATMENT HAS BEEN SHOWN TO MAINTAIN THE
EFFECTIVENESS OF RADIOTHERAPY ON TUMOR CELLS
    * CONTINUATION OF THIS PRECLINICAL WORK ON EFFECTIVENESS OF
NANOMANGANESE IS INCLUDED IN FINANCING PLAN PRESENTED ON 13
APRIL 2022 FOR CURRENT YEAR
    * RESULTS SHOW A TREND TOWARDS A POTENTIAL OF NANOMANGANESE
TO
SENSITIZE TUMOR CELLS TO RADIATION
    * VALIDATION WILL BE FOLLOWED BY CLINICAL PHASE II WHICH
WILL BE
PREPARED IN LATE 2022 FOR IMPLEMENTATION IN H1 2023
    * MEANS NANOMANGANESE COULD PROTECT HEALTHY TISSUES FROM THE
TOXICITY OF RADIOTHERAPY, BUT ALSO POTENTIATE THE EFFECTIVENESS
OF RADIOTHERAPY ON TUMOR CELLS

Source text for Eikon:  ID:nNDL1NrFtd 
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))